CTBO stock $1.01 14 Jan 2026 PNK hours: Oversold bounce may aid short entry
CTBO stock trades at $1.01 on 14 Jan 2026 during PNK market hours, presenting an oversold bounce setup for short-term traders. Volume is extremely light at 24 shares with an average of 8.00 shares, so small orders can move price quickly. The company is a preclinical biotechnology name focused on Parkinson’s and Alzheimer’s programs, and the financials show a negative EPS of -8.08. Given the stock’s thin liquidity, an oversold bounce strategy favors strict position sizing and tight stops to capture a short-lived rebound.
Quick snapshot: CTBO stock price and liquidity
CTBO stock is quoted at $1.01 on the PNK exchange in the United States with a market cap near $22,769.00. Trading activity today shows 24 shares versus an average volume of 8.00, producing a relative volume of 3.03. The company reports EPS of -8.08 and a PE of -0.12, and the share count stands at 22,544.00 outstanding.
Why an oversold bounce setup exists for CTBO stock
Price is effectively flat but the low float and minimal trading create outsized moves when buying interest appears. The stock’s short history of activity and concentrated ownership raise the chance of short-lived spikes. For an oversold bounce play, traders look for a quick pop above immediate resistance near $1.10 and volume confirmation rather than a sustained trend change.
Fundamentals and risk factors for Cantabio Pharmaceuticals, Inc.
Cantabio Pharmaceuticals, Inc. (CTBO) is a preclinical biotechnology firm focused on DJ-1 and Tau targets in Parkinson’s and Alzheimer’s disease. The firm lists CEO Gergely Toth and a collaboration with the Luxembourg Institute of Health. The small market cap and negative EPS indicate high development risk and likely dilution risk if the company raises capital.
Technical approach and practical trade plan for oversold bounce
A tactical trade plan: enter a small position on a decisive move above $1.10 with volume at least double the recent average. Set a stop-loss near $0.85 to limit downside to about -15.84%. Target a near-term take-profit at $1.20 for a potential +18.81% gain, and consider scaling out if volume confirms follow-through.
Meyka AI grade and CTBO stock forecast
Meyka AI rates CTBO with a score out of 100: Score 59.14 | Grade C+ | Suggestion: HOLD. This grade factors in S&P 500 comparison, sector performance, financial growth, key metrics, and analyst consensus. Meyka AI’s forecast model projects monthly and quarterly values of $1.01, a 1-year projection of $0.20, a 3-year projection of $0.66, a 5-year projection of $1.04, and a 7-year projection of $1.50. Versus the current price of $1.01, the model implies a -80.09% change at 1 year, -35.01% at 3 years, +3.08% at 5 years, and +48.16% at 7 years. Forecasts are model-based projections and not guarantees.
Sector context and trading considerations for CTBO stock
CTBO sits in the Healthcare sector and Biotechnology industry, both of which show persistent volatility tied to clinical and financing news. For short-term oversold bounces, watch biotech sector flows and any company news that could trigger volume. Given the thin trading, prioritize liquidity, use limit orders, and avoid oversizing any position.
Final Thoughts
Key takeaways on CTBO stock: the market quote of $1.01 on 14 Jan 2026 and the tiny volume (24) create an environment where an oversold bounce can produce sizable short-term moves. The Meyka AI grade is C+ (59.14), signaling a HOLD bias driven by weak fundamentals and scarce trading history. Our tactical plan favors a measured entry above $1.10, a stop near $0.85 (-15.84%), and a near-term target at $1.20 (+18.81%). Meyka AI’s forecast model shows divergent timelines: a 1-year projection of $0.20 (implied -80.09%) and a 7-year projection of $1.50 (implied +48.16%). These model outputs emphasize the long-term uncertainty for preclinical biotechs and the short-term trading opportunity from low liquidity. Use strict risk controls and limit position size to a small percentage of your portfolio when applying an oversold bounce strategy. For trade-level details and live order monitoring, see the Meyka AI stock page for CTBO and follow verified news triggers before entering a position.
FAQs
Is CTBO stock a buy right now?
CTBO stock is a speculative trade. Meyka AI assigns a C+ rating and suggests HOLD. For short-term traders, a small, controlled oversold bounce trade above $1.10 may be appropriate with a stop at $0.85.
What are the main risks for CTBO stock?
Primary risks include preclinical-stage development, negative EPS (-8.08), potential dilution from future funding, and extremely low liquidity that can amplify price swings in CTBO stock.
What price targets should traders use for CTBO stock?
A tactical short-term target is $1.20 (+18.81%) with a stop near $0.85 (-15.84%). Meyka AI’s model gives a 5-year projection of $1.04 and a 7-year projection of $1.50, but these are model-based and not guarantees.
Disclaimer:
Stock markets involve risks. This content is for informational purposes only. Past performance does not guarantee future results. Meyka AI PTY LTD provides market analysis and data insights, not financial advice. Always conduct your own research and consider consulting a licensed financial advisor.
